LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
Lakefront Biotherapeutics NV
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026
$29.79−0.11 (-0.37%)
Close on Oct 19, 2026
Lakefront Biotherapeutics statistics
Financials through Dec 31, 2025, price-based ratios appear once a share price is available, median of Pharmaceutical Preparations companies for comparison
Income (trailing twelve months)
| Measure | Lakefront Biotherapeutics | Industry median |
|---|---|---|
| Revenue | €1.11B | €447.40M |
| Gross Profit | €1.08B | €1.08B |
| Operating Income | €295.04M | -€68.03M |
| Pretax Income | €300.87M | -€49.18M |
| Net Income | €320.88M | -€6.53M |
| EBITDA | €295.04M | -€48.04M |
| EPS (Diluted) | 4.87 EUR | -0.61 EUR |
Margins
| Measure | Lakefront Biotherapeutics | Industry median |
|---|---|---|
| Gross Margin | 97.3% | 42.8% |
| Operating Margin | 26.5% | -33.2% |
| Pretax Margin | 27.1% | -36.6% |
| Profit Margin | 28.8% | -31.7% |
| EBITDA Margin | 26.5% | -28.6% |
| FCF Margin | -24.4% | -24.4% |
Returns
| Measure | Lakefront Biotherapeutics | Industry median |
|---|---|---|
| Return on Assets (ROA) | 8.51% | -5.10% |
| Return on Capital Employed (ROCE) | 9.07% | -26.9% |
Growth
| Measure | Lakefront Biotherapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 303.5% | 1.99% |
| Net Income Growth (YoY) | 333.1% | |
| EPS Growth (YoY) | 334.8% | 67.4% |
| Revenue Growth (3Y CAGR) | 66.4% | 13.5% |
| Revenue Growth (5Y CAGR) | 18.4% | 11.0% |
Balance sheet
| Measure | Lakefront Biotherapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | €87.87M | €291.68M |
| Net Cash (Debt) | €87.87M | €87.54M |
| Net Cash Per Share | 1.33 EUR | 1.09 EUR |
| Working Capital | €2.93B | €121.78M |
Financial position
| Measure | Lakefront Biotherapeutics | Industry median |
|---|---|---|
| Current Ratio | 20.15 | 2.81 |
| Quick Ratio | 0.71 | 1.23 |
| Interest Coverage | 285.34 | -0.90 |
Cash flow (trailing twelve months)
| Measure | Lakefront Biotherapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -€257.46M | -€35.31M |
| Capital Expenditures | -€13.70M | -€4.42M |
| Free Cash Flow | -€271.16M | -€53.81M |
| FCF Per Share | -4.11 EUR | -0.56 EUR |
Efficiency
| Measure | Lakefront Biotherapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.29 | 0.32 |
| Inventory Turnover | 0.81 | 1.33 |
| Revenue Per Employee | €2.46M | €420.86K |
| Profits Per Employee | €709.92K | -€247.02K |
| Employee Count | 452 | 378 |
Shares
| Measure | Lakefront Biotherapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 65,897,100 | 105,361,000 |
| Shares Change (YoY) | 0.00% | 6.28% |
| Float | 36,201,500 | 78,574,400 |
| Shares Held by Insiders | 45.1% | 9.05% |
| Shares Held by Institutions | 48.6% | 13.8% |
Taxes
| Measure | Lakefront Biotherapeutics | Industry median |
|---|---|---|
| Income Tax | -€18.62M | €1.53M |
| Effective Tax Rate | -6.19% |
Scores
| Measure | Lakefront Biotherapeutics | Industry median |
|---|---|---|
| Piotroski F-Score | 7 | 5 |
Calculated by StockData from Lakefront Biotherapeutics's SEC filings. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.